Loading...
Please wait, while we are loading the content...
Similar Documents
Acquired ALK Resistance Mutations Identified from Liquid Biopsy in an ALK-Rearranged Squamous Cell Lung Cancer Patient Treated with Sequential ALK TKI Therapy: A Case Report
| Content Provider | Scilit |
|---|---|
| Author | Yao, Bin Han, Xue Pang, Linrong Xu, Caihong Liu, Sisi Cheng, Xiaochun Chen, Jun |
| Copyright Year | 2021 |
| Description | Anaplastic lymphoma kinase (ALK) rearrangement is extremely rare in lung squamous cell carcinoma (LSCC), and it remains controversial as to whether LSCC patients with ALK rearrangement can benefit from ALK tyrosine kinase inhibitors (TKIs). Here, we report an LSCC patient with ALK rearrangement who was treated with sequential ALK TKI therapies and experienced a clinical benefit of 35 months. Although the use of ALK TKIs showed clinical benefits, targeted next-generation sequencing (NGS) for dynamic monitoring of circulating tumor DNA (ctDNA) from patient plasma revealed the accumulation of ALK resistance mutations, which could provide valuable information in designing the treatment strategy. Our study highlights the importance of dynamic monitoring of ctDNA using NGS to discover tumor evolution to guide treatment decision-making and provides meaningful insights into the potential treatment options for ALK-positive LSCC patients. |
| Related Links | https://www.dovepress.com/getfile.php?fileID=72267 |
| Ending Page | 4333 |
| Page Count | 5 |
| Starting Page | 4329 |
| ISSN | 11786930 |
| DOI | 10.2147/ott.s315832 |
| Journal | OncoTargets and therapy |
| Volume Number | 14 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2021-08-01 |
| Access Restriction | Open |
| Subject Keyword | Oncology Alk Rearrangement Dynamic Monitoring Resistance Mutation Next-generation Sequencing |
| Content Type | Text |
| Resource Type | Article |
| Subject | Pharmacology (medical) Oncology |
